Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

Aged Basal Metabolism Body Composition Cachexia / diagnosis Calorimetry, Indirect Carcinoma, Non-Small-Cell Lung / metabolism Energy Metabolism Female Humans Lung Neoplasms / metabolism Male Middle Aged Prognosis Prospective Studies Risk Assessment Risk Factors Time Factors Up-Regulation
Malnutrition Non-small cell lung cancer Prognosis Resting energy expenditure Survival

Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
06 2020
Historique:
received: 21 06 2019
revised: 30 07 2019
accepted: 05 08 2019
pubmed: 25 8 2019
medline: 17 8 2021
entrez: 25 8 2019
Statut: ppublish

Résumé

Metastatic non-small cell lung cancer (NSCLC) is the first cause of cancer death worldwide. Increased resting energy expenditure (REE) is frequent among cancer patients and may contribute to cancer cachexia. The aim of this study was to examine the prognostic value of increased REE in metastatic NSCLC patients. This observational study was conducted between June 2012 and November 2017 in the outpatient unit of the oncology department of Cochin hospital, Paris. Consecutive patients with newly diagnosed stage IV NSCLC underwent measurement of REE by indirect calorimetry before treatment initiation. Uni- and multivariate analysis of overall survival (OS, Cox models) included age, sex, smoking habit, histological subtype, performance status, body mass index, weight loss, albumin and CRP levels and the ratio of measured REE to the REE predicted by the Harris Benedict formula (mREE/pREE). 144 patients were enrolled: mean age 64 years, 63% male, 90% non-squamous carcinoma, including 17% with ALK/EGFR alteration. In univariate analysis, tobacco consumption (p = 0.007), histo-molecular subtype (p < 10 Elevated resting energy expenditure emerges as an independent prognostic factor in metastatic NSCLC.

Sections du résumé

BACKGROUND & AIMS
Metastatic non-small cell lung cancer (NSCLC) is the first cause of cancer death worldwide. Increased resting energy expenditure (REE) is frequent among cancer patients and may contribute to cancer cachexia. The aim of this study was to examine the prognostic value of increased REE in metastatic NSCLC patients.
METHODS
This observational study was conducted between June 2012 and November 2017 in the outpatient unit of the oncology department of Cochin hospital, Paris. Consecutive patients with newly diagnosed stage IV NSCLC underwent measurement of REE by indirect calorimetry before treatment initiation. Uni- and multivariate analysis of overall survival (OS, Cox models) included age, sex, smoking habit, histological subtype, performance status, body mass index, weight loss, albumin and CRP levels and the ratio of measured REE to the REE predicted by the Harris Benedict formula (mREE/pREE).
RESULTS
144 patients were enrolled: mean age 64 years, 63% male, 90% non-squamous carcinoma, including 17% with ALK/EGFR alteration. In univariate analysis, tobacco consumption (p = 0.007), histo-molecular subtype (p < 10
CONCLUSIONS
Elevated resting energy expenditure emerges as an independent prognostic factor in metastatic NSCLC.

Identifiants

DOI: 10.1016/j.clnu.2019.08.003 PMID: 31443979
pubmed: 31443979
pii: S0261-5614(19)30315-2
doi: 10.1016/j.clnu.2019.08.003
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1893-1899

Informations de copyright

Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Auteurs

Anne Jouinot (A)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France; Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris, France. Electronic address: anne.jouinot@aphp.fr.

Guillaume Ulmann (G)

Clinical Chemistry, Paris Centre Teaching Hospitals, AP-HP, Paris Descartes University, USPC, Paris, France; EA 4466 PRETRAM, Pharmacy Faculty, Paris Descartes University, USPC, Paris, France.

Clara Vazeille (C)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France.

Jean-Philippe Durand (JP)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France; EA 4466 PRETRAM, Pharmacy Faculty, Paris Descartes University, USPC, Paris, France.

Pascaline Boudou-Rouquette (P)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France.

Jennifer Arrondeau (J)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France.

Camille Tlemsani (C)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France.

Ludovic Fournel (L)

Thoracic Surgery Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Paris Descartes University, Paris, France.

Marco Alifano (M)

Thoracic Surgery Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Paris Descartes University, Paris, France.

Marie Wislez (M)

Pneumology Department, Paris Centre Teaching Hospitals, AP-HP, Paris Descartes University, USPC, Paris, France.

Jeanne Chapron (J)

Pneumology Department, Paris Centre Teaching Hospitals, AP-HP, Paris Descartes University, USPC, Paris, France.

Camille Le Bris (C)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France.

Audrey Mansuet-Lupo (A)

Pathology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Centre de recherche des Cordeliers, INSERM U1138, Paris Descartes University, USPC, Paris, France.

Diane Damotte (D)

Pathology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Centre de recherche des Cordeliers, INSERM U1138, Paris Descartes University, USPC, Paris, France.

Nathalie Neveux (N)

Clinical Chemistry, Paris Centre Teaching Hospitals, AP-HP, Paris Descartes University, USPC, Paris, France; EA 4466 PRETRAM, Pharmacy Faculty, Paris Descartes University, USPC, Paris, France.

Jean-Pascal De Bandt (JP)

Clinical Chemistry, Paris Centre Teaching Hospitals, AP-HP, Paris Descartes University, USPC, Paris, France; EA 4466 PRETRAM, Pharmacy Faculty, Paris Descartes University, USPC, Paris, France.

Jérôme Alexandre (J)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France.

Luc Cynober (L)

Clinical Chemistry, Paris Centre Teaching Hospitals, AP-HP, Paris Descartes University, USPC, Paris, France; EA 4466 PRETRAM, Pharmacy Faculty, Paris Descartes University, USPC, Paris, France.

François Goldwasser (F)

Medical Oncology Department, Paris Centre Teaching Hospitals, AP-HP, Paris, France; Cancer Research for PErsonalized Medicine (CARPEM), Paris, France; Paris Descartes University, USPC, Paris, France; EA 4466 PRETRAM, Pharmacy Faculty, Paris Descartes University, USPC, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Métabolisme › Métabolisme énergétique › Métabolisme basal › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Phénomènes physiologiques › Constitution physique › Composition corporelle › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Cachexie › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Calorimétrie › Calorimétrie indirecte › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Métabolisme › Métabolisme énergétique › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Diagnostic › Pronostic › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Hypermetabolism is an independent prognostic...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › Hypermetabolism is an independent prognostic...